Published in final edited form as:

Biomaterials. 2010 August ; 31(22): 5741–5748. doi:10.1016/j.biomaterials.2010.03.074.

BRADYKININ FORMING CAPACITY OF OVERSULFATED CHONDROITIN SULFATE CONTAMINATED HEPARIN *IN VITRO*

Albert Adam^a, Nicolas Montpas^a, David Keire^b, Anik Désormeaux^a, Nancy J. Brown^c, François Marceau^d, and Benjamin Westenberger^b

^aFaculty of Pharmacy, Université de Montréal, Montréal, Qc, H3T 1J4, Canada

^bU.S. Food and Drug Administration, Division of Pharmaceutical Analysis, St-Louis, MO 63101, USA

^cClinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA

^dRheumatology and Immunology Research Center, CHUL-CHUQ, Québec, Qc, G1V 4G2, Canada

Abstract

Oversulfated chondroitin sulfate (OSCS) contaminated heparin has been associated with severe anaphylactoid reaction (AR), mainly in dialysed patients. Although attributed to bradykinin (BK) released during contact system activation by OSCS, no definitive evidence exists until now for a BK release during incubation of contaminated heparin with human plasma. In this study, we investigated the kinin forming capacity of OSCS and OSCS contaminated heparin when incubated *in vitro* with a pool of human plasma. At 100µg/mL, OSCS liberates BK in a profile similar but not identical to dextran sulfate, a well known activator of the plasma contact system. The results have highlighted that the quantity of BK accumulated during contact system activation depends not only on the concentration of OSCS but also on the plasma dilution and the presence of an angiotensin converting enzyme inhibitor. We demonstrate a highly significant correlation between the concentration of OSCS present in the contaminated heparin and BK released concentration. In conclusion, for the first time, we show that OSCS contaminated heparin incubated with human plasma has the capacity to liberate BK at a concentration that could explain the role of this inflammatory peptide in the pathophysiology of AR associated with OSCS contaminated heparin.

Keywords

Heparin; oversulfated chondroitin sulfate; bradykinin; anaphylactoid reaction

1. Introduction

Anaphylactic-like or anaphylactoid reactions (AR) have been associated with the injection of heparin manufactured in China, late in 2007 and in 2008 [1,2]. Hundreds of AR were observed mainly in the United States and in Germany, and 159 deaths were reported to the Food and

© 2010 Elsevier Ltd. All rights reserved.

Corresponding author: Albert Adam, Faculté de pharmacie, Université de Montréal, 2900, Boulevard E Montpetit, H3T 1J4 MONTRÉAL, CANADA. Phone: 514-343-2026. Fax: 514-343-2102. albert.adam@umontreal.ca.

Disclaimer: The findings and conclusions in this article have not been formally disseminated by the Food and Drug Administration and should not be construed to represent any Agency determination or policy.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Drug Administration (FDA) [3]. These AR, observed mainly in hemodialysis patients at the beginning of the dialysis session, were characterized by hypotension, tachycardia, angioedema, urticaria and nausea. Similar symptoms have been reported in patients dialyzed with a negatively charged membrane (made primarily of polyacrylonitrile) and simultaneously treated with an angiotensin converting enzyme inhibitor (ACEi) [4,5].

Physicochemical investigation of the different batches of heparin associated with these AR revealed that these heparin solutions were contaminated with oversulfated chondroitin sulfate (OSCS) [6], a synthetic product obtained by oversulfatation of the natural chondroitin sulfate A (CSA) [7]. Synthetic OSCS and the OSCS present in contaminated batches of heparin obtained from the marketplace by the FDA were investigated for their capacity to activate the plasma contact system which can lead to the release of bradykinin (BK), a vasoactive peptide potentially responsible for the symptoms associated with these AR. These authors measured a serine protease activity using a synthetic substrate to assay the contact system activation [8]. As noted by Ramaciotti *et al.*, however, no definitive evidence has existed for BK release during human plasma contact with OSCS and/or OSCS contaminated heparin [9]. In this work we demonstrate the BK release by OSCS and by OSCS contaminated.

The contact system of plasma consists in 3 proenzymes: Hageman factor (factor XII, FXII), factor XI (FXI) of the coagulation and prekallikrein (pKK). PKK and FXI circulate in plasma complexed with a cofactor, high-molecular-weight kininogen (HMW-kininogen). The contact of plasma with a negative surface like dextran sulfate (DxS) [10,11], glass beads [12], or polyacrylonitrile membrane [13,14] leads to the binding of FXII and HMW-kininogen. This binding of FXII is responsible for its auto activation. Activated FXII (FXIIa) in turn activates FXI and transforms pKK into an active serine protease kallikrein (KK). Both FXIIa and KK are responsible for the amidolytic activity reported earlier by Kishimoto *et al.* [8]. KK hydrolyses HMW-kininogen and releases BK. BK is a powerful vasodilator and proinflammatory nonapeptide which exerts its pharmacological activities by stimulation of B2 receptors. Importantly, BK has a very short half life due to the presence of peptidases in the circulation. In human plasma, BK is primarily metabolised by angiotensin converting enzyme (ACE) and secondarily by aminopeptidase P (APP) or carboxypeptidase N (CPN) [12].

The objective of our study was to measure the kinetics of BK release and to characterize BK immunoreactivity in human plasma incubated with OSCS. As a control we compared the values observed for OSCS with DxS, a well known contact system activator [10,11]. As the AR associated with OSCS contaminated heparin occurred mainly in the first minutes of dialysis session [1], we also studied the effect of the plasma dilution on the amount of BK released in the presence of an ACE inhibitor, a cardiovascular drug commonly used in dialysed patients. Finally, we quantify the BK forming capacity of different batches of OSCS contaminated heparin responsible for AR and we compare this effect with reference heparin spiked or not with increasing concentrations of synthetic OSCS.

2. Material and methods

The experimental protocol was approved by the Ethics Committee of the Université de Montréal

2.1. Reagents

OSCS was synthesized by the US Food and Drug Administration/Division of Pharmaceutical Analysis (FDA/DPA) laboratory in St-Louis [7]. Different batches of OSCS contaminated heparin were collected from the marketplace by FDA consumer safety officers and sent to the FDA/DPA in St-Louis for analysis. OSCS levels were measured using a strong-anion-exchange-HPLC method [15,16]. DxS, chondroitin sulfate A (CSA) and chondroitin sulfate B

(CSB, aka dermatan sulfate or DS) and vehicle (phosphate buffered saline; PBS) were from Sigma Aldrich (Oakville, ON, Canada). The ACEi, enalaprilat, was obtained from Merck Frost Canada (Kirkland, QC, Canada). Reagents of analytical grade were purchased from Fisher Scientific (St-Laurent, QC, Canada) unless specified otherwise.

2.2. Plasma collection

The different activation processes were assayed on a pool of plasma samples (n=5) obtained from healthy volunteers. Eighteen millilitres of total venous blood were collected using a polypropylene catheter from the forearm of each donor into a polypropylene tube containing 2 mL of 0.1 M sodium citrate pH 7.4. After centrifugation (22 °C, 15 min, 2500 g) the plasmas were decanted, pooled and stored at -80 °C until *in vitro* experiments. On the day of experiment, the pool of plasmas was thawed and vortexed carefully. This protocol has been shown to avoid *in vitro* contact system activation [12].

2.3. Preparation of stock solutions of the different activators of the contact system

A stock solution of the different activators to be tested (DxS, OSCS, CSA, CSB, non contaminated and OSCS contaminated heparin) was prepared in standardized conditions: Solutions of 10 mg/mL in PBS buffer in polypropylene tubes were made. These stock solutions were stored at -80 °C until use. At the time of use, these different solutions were thawed in the same conditions: 60 min at room temperature. Then, after vortexing 30 sec, they were diluted to the tested concentrations.

2.4. Incubations of plasma

The different incubation processes were made at 37 °C in polypropylene tubes and used 1 volume of activator solution for 9 volumes of plasma pre-incubated for 20 min with an ACEi, enalaprilat at a final concentration of 520 nM [12].

2.4.1. Comparative effect of DxS and OSCS on BK release during plasma

activation—900 µL of pre-incubated plasma was mixed with 100 µL of OSCS or DxS stock solution to obtain a final concentration of 1, 10, 100 or 1000 µg/mL and incubated with agitation at 37 °C. At different intervals (0, 5, 10, 20, 40, 60 and 120 min), 50 µL of the incubation mixture was added into 2 mL of ice-cold 80% ethanol. Samples were incubated for 1 hr on ice before centrifugation for 15 min at 3000 g and 4 °C. Supernatants were collected and evaporated to dryness over-night in a Speed Vac Plus (Savant, Farmingdale, NY, USA). A similar incubation procedure was used to test the kinin forming capacity of CSA or B and heparin at a final concentration of 100µg/mL. This time course of incubation and samples processing were used for the different incubations described here after. In each case, 9 volumes of plasma added with 1 volume of PBS buffer, preincubated with enalaprilat and incubated in polypropylene tube under the same conditions were used as a control.

2.4.2. Effect of plasma dilution and ACE inhibition on the profile of BK released during contact system activation by OSCS

—Successive dilutions of plasma (90,80,60,40 and 20% with Tris 50mM/NaCl 150 mM pH 7.4), pre-incubated with enalaprilat as described above were mixed with OSCS or DxS to obtain a final concentration of 100 µg/mL. To define the effect of ACE inhibition, 900 µL of diluted plasma was pre-incubated or not with the ACEi and these samples were incubated with OSCS at the 100 µg/mL final concentration.

2.4.3. Kinin forming capacity of non contaminated heparin and of the different batches of OSCS contaminated heparin

—900 µL of diluted plasma pre-incubated with enalaprilat were incubated with the different batches of heparin summarized in Table 1. Among

the different batches of active pharmaceutical ingredients (API) obtained from the marketplace, heparin API samples containing 24.3, 16.7 and 3.1 weight percent OSCS had been used to formulate drug products which have been associated with severe AR. Here, the different samples were tested at a total 410 µg/mL concentration of heparin in the incubation medium. The 410 µg/mL concentration of heparin corresponds to 100 µg/mL of OSCS for the most (24.3%) contaminated sample (sample #10).

2.5. Quantification of immunoreactive BK

Residues of evaporated ethanolic extracts were re-suspended in 50 mM Tris/HCl buffer, pH 7.4, containing 100 mM NaCl and 0.05% Tween-20. After re-suspension, BK was quantified by a specific competitive enzyme immunoassay, as described previously [17,18]. This method has been validated and its analytical performances reported [19].

2.6. Physicochemical and pharmacological characterization of immunoreactive BK

Residues of the evaporated ethanolic extracts containing immunoreactive BK following diluted plasma activation by DxS or OSCS (100 µg/mL), contaminated heparin (sample #10, 100 µg/mL of contaminant) or without any reagent in presence of enalaprilat were used for the physicochemical and the pharmacological characterization. This physicochemical characterization was obtained by HPLC separation combined with competitive enzyme immunoassay as described in Moreau et al. [20]. Retention time of each immunoreactive fraction was compared to that of standard peptides. The BK-like pharmacologic activity of immunoreactive BK was measured using an ERK1/2 MAP kinase phosphorylation assay in HEK 293 cells stably expressing the rabbit B₂ receptor conjugated to green fluorescent protein (B₂R-GFP) [21]. This assay is responsive to nanomolar BK concentration and, as a B₂ receptor mediated response, should not respond to any of BK fragments which exhibit very low affinity at this receptor. Briefly, HEK 293 cells stably expressing B₂R-GFP grown in 25cm² flasks were treated for 10 min with the dried extracts of the treated plasmas, diluted in sterile saline, combined or not with the B₂ receptor antagonist LF16-0687 (gift from Laboratoires Fournier, Daix, France[22]), in the regular, serum-containing culture medium. Total cell lysates were recovered and analyzed after SDS/PAGE (9% gel, general methods as in [23]) and protein transfer using anti-phospho-ERK1/2 and -total ERK 1/2 (respectively, monoclonals and polyclonals, Cell Signaling Technology, 1:1000 for each) that were used in conjunction with appropriate horseradish peroxidase-conjugated secondary antibodies.

2.8. Statistical analysis

Results are expressed as mean ± standard error of the mean (SEM). The quantity of BK released in different experimental conditions was used to calculate the area under curve (AUC) of the kinetic profile. The AUC for BK was calculated by summing the area of the different quadrilaterals obtained by joining kinin concentrations measured at consecutive times calculated by GraphPad Prism 4.0 software. Two sample t tests were used to compare the AUC and the peak concentration of BK released. A $p \leq 0.01$ was considered significant for the different comparisons [24].

3. Results

3.1. Comparative BK forming capacity of OSCS and DxS in human plasma

Figure 1A shows the kinetic profiles of BK released in the pool of plasma when incubated with DxS or OSCS at a 100 µg/mL final concentration. The peak concentration of BK released during the activation of plasma by OSCS (115 ± 28 pmol/mL) is significantly lower than this measured with DxS (377 ± 42 pmol/mL). Moreover, this peak is observed later (19.2 ± 0.6 min) than that of DxS (7.2 ± 0.4 min). The area under the curve (AUC) which represent the

total BK released during the 120 min incubation process with OSCS at concentrations ranging from 1 to 1000 $\mu\text{g/mL}$ are illustrated in figure 1B along with these measured for DxS. These total BK released showed that incubations with DxS concentrations of 1 or 10 $\mu\text{g/mL}$ leads to a BK accumulation in the nmol range (1.86 ± 0.02 nmol and 1.58 ± 0.03 nmol). These BK accumulations reach rapidly a plateau with the highest DxS concentrations in plasma (11.38 ± 0.72 nmol and 10.76 ± 0.15 nmol for 100 $\mu\text{g/mL}$ and 1000 $\mu\text{g/mL}$ DxS respectively). In contrast, the AUC of BK released in plasma incubated with 1, 10, 100 and 1000 $\mu\text{g/mL}$ of OSCS demonstrated a dose-dependent profile (respectively 1.31 ± 0.02 , 2.84 ± 0.02 , 5.31 ± 0.49 and 9.15 ± 0.09 nmol of BK). A concentration of both activators as low as 1 $\mu\text{g/mL}$ leads to the release of a quantity of BK (1.86 ± 0.02 and 1.31 ± 0.02 nmol) significantly higher than this measured in the plasma control incubated in the same conditions (0.38 ± 0.02 nmol of BK).

With the same incubation conditions, the quantity of BK measured in presence of 100 $\mu\text{g/mL}$ of CSA, CSB and heparin (respectively 0.57 ± 0.01 , 0.63 ± 0.01 nmol and 2.38 ± 0.06 nmol of BK) was significantly lower than that observed for OSCS at 100 $\mu\text{g/mL}$ (5.31 ± 0.49 nmol) although significantly higher than that measured in absence of any activator (0.38 ± 0.02 nmol) (Figure 2B). However, for CSA, CSB and heparin, no peak concentrations in the kinetic profiles were observed, in contrast to the OSCS activation.

3.2. Effect of plasma dilution on the BK forming capacity of OSCS

The quantity of BK released during the incubation of plasma pool with OSCS (from 5.31 ± 0.49 to 31.88 ± 0.50 nmol) or DxS (from 11.38 ± 0.72 to 40.4 ± 1.14 nmol) increases progressively when plasma is successively diluted from 90 to 20% (Figure 3). Because dilutions in the range of 40 to 60% mimic the dilution of plasma in the dialyser at the connection during a hemodialysis session we chose a 50% dilution of plasma for subsequent experiments.

3.3. Effect of the ACE inhibition on the BK forming capacity of OSCS

With a 50% dilution of plasma, the presence of an ACEi significantly modifies the metabolic profile of BK released when plasma is incubated with 100 μg of OSCS (Figure 4). Effectively, the second part of these BK kinetic profiles demonstrated that ACEi slowed BK degradation and concomitantly leads to BK accumulation over a longer period of time. Due to the inhibition of the main pathway of BK degradation, the AUC in presence of enalaprilat (12.26 ± 0.21 nmol) was significantly higher than in absence of this inhibitor (3.93 ± 0.06 nmol).

3.4. Kinin forming capacity of non-contaminated heparin and of the different batches of OSCS contaminated- or synthetic OSCS spiked-heparin

As illustrated in Figure 5, incubation of 50% diluted plasma in presence of an ACEi and of 410 μg of heparin containing 100 μg of OSCS leads to a kinetic profile of BK which is totally different from these obtained in presence of the same concentration of uncontaminated heparin and for the control plasma. The AUC observed in presence of heparin containing 24.3% of OSCS (7.4 ± 0.15 nmol) is more than 2.5 times higher than this measured for heparin alone (2.9 ± 0.33 nmol).

Moreover, no peak concentration of BK could be observed in the kinetic profile of plasma incubated with non-contaminated heparin, contrarily to plasma incubated with contaminated heparin. When the BK concentration reached a peak value (92.0 ± 3.7 pmol/mL) in plasma incubated with OSCS contaminated heparin, the maximum concentration of BK observed in presence of non-contaminated heparin was more than 3.5 times lower (25.4 ± 2.5 pmol/mL).

As shown in figure 6, a correlation could be calculated between the weight % OSCS in heparin the maximum concentration ($y = 2.04x + 38.10$; $R^2 = 0.93$) or the total quantity ($y = 0.150x + 3.535$; $R^2 = 0.87$) of BK released in plasma during the incubation process. Moreover, batches

of OSCS contaminated heparin which were associated with cases of AR have all led to a significantly higher release of BK in plasma.

3.5. Physicochemical and pharmacologic characterization of immunoreactive BK released during plasma contact system activation

After HPLC chromatography of ethanolic extracts of plasma incubated with DxS, OSCS or contaminated heparin, immunoreactivity could be detected only at the retention time (24.1 min) which corresponds to the native BK.

HEK 293 cells that stably expressed a recombinant BK receptor (B₂R-GFP) were exposed to human plasmas (pre-reacted with OSCS, contaminated heparin or DxS) extracted with ethanol and the ERK1/2 MAP kinases phosphorylation probed via specific antibodies (Figure 7A). A similar ethanol extraction from control incubated human plasma did not activate ERK1/2 phosphorylation. Extracts from contaminated heparin- or OSCS-treated plasmas lost effectiveness for p-ERK1/2 upon dilution of the extracts (Figure 7B). A calibration with authentic BK estimated the kinin content of the 1:45 diluted plasmas extracts around 10 nM of BK, congruent with the concentration determined with the BK immunoassay run in the same samples. The pharmacological activity of treated plasmas was essentially lost when cells were pre-treated with the BK B₂ receptor antagonist LF16-0687 (Figure 7C).

4. Discussion

In this work, we provide evidence for the first time that OSCS has the capacity to liberate BK when incubated with human plasma. We show that the quantity of BK released in presence of OSCS depends not only on ACE inhibition but also on plasma dilution. Moreover, experiments quantifying plasma activation by different batches of OSCS contaminated heparin and heparin spiked with different OSCS quantities demonstrated a correlation between the OSCS contaminant level and the quantity of BK released. Our results complete a former report which presented an indirect evidence for the participation of BK in the pathogenesis of these acute and potentially lethal AR associated with different batches of heparin contaminated with OSCS. *Kishimoto et al.* [8] measured an increase in amidolytic activity reflecting the enzyme activity of KK and to a lesser extent FXIIa, during contact system activation when either OSCS or different batches of contaminated heparin were incubated *in vitro* with human plasma. Increased enzyme activity doesn't indicate that BK is present in plasma during the incubation processes, however. In fact, the plasma concentration of BK potentially responsible for these AR depends not only on BK release but also on the metabolism of the peptide in the circulation which is decreased in presence of an ACEi [12].

In preliminary assays, we have carefully defined the experimental conditions that yield reproducible results with the different activators. Because these activators are of biological origin, heterogeneity can be present and affect the precision and accuracy of the assays.

In a first set of experiments, we have compared the kinin forming capacity of OSCS with that of DxS. DxS is a well known activator of the plasma contact system and is currently used in coagulation tests at a µg/mL concentration [25,26]. Earlier, we also used DxS at a similar concentration to measure the amidolytic activity of kallikrein during the activation of plasma [27,28].

These incubations were performed in the presence of an ACEi for 3 reasons. First, ACEi blocks the main degrading pathway of BK in plasma leading to a higher accumulation of the B₂ agonist during the kinetic contact system activation. Second, as the symptoms of AR associated with OSCS contaminated heparin mimic AR reported in ACEi-treated patients who were dialysed with a negatively charged membrane [2], we proposed that the presence of ACEi could play a

role in the pathophysiology of OSCS associated AR because of the similarity in the negative charge density of OSCS and negatively charged dialysis membranes [4,5]. Finally, Blossom *et al.* [29] have reported that 25 % of dialysed patients who presented with an AR associated with OSCS contaminated heparin were treated with an ACEi.

In support of the hypothesis that both kinds of AR share a similar mechanism, we show a correlation between OSCS concentration and the concentration of BK released in the presence of an ACEi. In addition, the quantity of BK released in the presence of OSCS (final concentration: 100 µg/mL) was lower than that measured in presence of DxS, but was higher than that measured in presence of CSA or CSB and heparin at the same concentration. For concentrations of OSCS as low as 1 µg/mL accumulation of BK in the nmol range could still be measured. These concentrations are higher than those measured in experimental rat models of inflammation triggered by contact system activation [17,30].

In our studies, the time of BK peak concentration occurs later for OSCS than for DxS. This could suggest the activation of fibrinolysis, another important kinin forming system [31]. Although Carranza *et al.* [32,33] have recently reported that OSCS enhances activation of plasminogen by tissue plasminogen activator (tPA), we could not show that OSCS *per se* triggers the kinin forming capacity of plasminogen, contrarily to rtPA (data not shown). These differences could be due to the structural differences between DxS and OSCS. Dextran sulfate is primarily sulfated α -1,6 linked glucose while OSCS is primarily a glucuronic acid 1,3 linked to N-acetylglucosamine disaccharide unit with the disaccharide units 1,4 linked to form the polymer. In addition, the DxS used in this study was 17% by weight sulphur while OSCS was 14% sulphur. Finally the DxS used here has a larger average molecular weight of >500 kDa while OSCS is approximately 18 kDa. As the AR associated with OSCS contaminated heparin occurred in the first minutes of the dialysis session [1,2], we have tested whether plasma dilution affected the BK quantity detected during the activation process. We observed a progressive increase in BK concentrations when the plasma was diluted from 90 to 20%. Two main causes could explain this accumulation. First, there could be an imbalance between the level of proteases (FXIIa and KK) and the anti-proteases responsible for the inhibition of their serine protease activity (mainly C1 inhibitor) [34]. Second, there could be a progressive decrease in the two pathways responsible for the metabolism of BK in presence of an ACEi: APP and CPN [12].

For testing the different batches of OSCS contaminated or spiked heparin, we chose a plasma dilution of 50% compatible to the dilution of blood in the dialyser at the time of patient connection. Under these conditions, we observed a significant correlation between the concentration of OSCS contaminant in heparin or the added synthetic OSCS, the peak concentration and the total quantity of BK released during the activation of the contact system. Moreover, we found the same correlation for both types of adulterated heparin samples suggesting the ingredient identified in contaminated heparin releases BK in human plasma in a similar manner to synthetic fully oversulfated CSA (4 sulfates/disaccharide unit).

The physicochemical and pharmacological characterisations of immunoreactive BK also support the participation of BK in the pathophysiology of OSCS associated AR. Previous investigators reported that contaminated heparin induces a transient hypotensive reaction when injected in a small number of pigs [8]. Here we measured BK by immunodetection following HPLC separation, confirming that the immunoreactivity measured during the activation of the contact system corresponds to the native B2 receptor agonist. More importantly, we established the specificity of the OSCS mediated pharmacological effect by demonstrating that the effect was suppressed with a B2 receptor of kinin antagonist, B2 receptor antagonism also prevented the AR associated with polyacrylonitrile membrane [14].

The final question we have to answer is: “Are our results relevant to the pathophysiology of OSCS contaminated heparin adverse events?” The total quantity of pharmacologically active BK released by incubation of plasma with the different batches of OSCS contaminated heparin is significantly higher than non contaminated heparin. These results were obtained with a plasma concentration of heparin (410 ug / mL) which is representative of what we found *in vivo* with a bolus injection [35] and a concentration of OSCS of 100 ug / mL of plasma *in vivo* could be obtained if the injected heparin is contaminated with 24.3% of OSCS. These values are the total amount measured by the AUC and correlate with the peak concentrations observed with the different incubation conditions and correspond to the hydrolysis of an equal nmol number of HMW-kininogen during plasma contact system activation. Such quantities of hydrolysed HMW-kininogen (or BK released) are in the same range as those measured in patients treated with an ACEi and presenting an AR while dialysed with a negatively charged membrane [36]. Similarly, *in vivo*, we have reported that DxS intravenously injected in rabbit treated with an ACEi leads to an important hypotensive reaction corresponding specifically to the hydrolysis of HMW-kininogen and to BK release, as shown by the suppression of the hypotensive reaction by injection of a B2 receptor antagonist [37].

5. Conclusions

The globalization of the heparin supply chain and the OSCS contamination of heparin in 2007-2008 highlight the need for careful screening of heparin for biomaterials that could lead to adverse reactions in patients. In this work, we show that OSCS, a synthetic contaminant added to heparin, has the capacity to liberate BK during *in vitro* activation of the contact system at a concentration that is compatible with its participation in the pathophysiology of the severe and potentially lethal AR associated with contaminated heparin. In addition, the experimental approach developed in this paper could be useful in the future to explore any bradykinin-link adverse reactions associated with biomaterials added to heparin for economic gain. Finally, this method could also be used to test for and prevent any unforeseen side effects that could be associated with the bio-engineered heparin now in development [38]

Acknowledgments

The work of AA is funded by the Canadian Institutes of Health Research (Grant MOP-93773; in collaboration with FM) and the National Institutes of Health (NIH Grant 1-R01-HL079184; in collaboration with NJB).

References

1. Acute allergic-type reactions among patients undergoing hemodialysis--multiple states, 2007-2008. MMWR Morb Mortal Wkly Rep 2008;57(5):124-5. [PubMed: 18256585]
2. Laurencin CT, Nair L. The FDA and safety--beyond the heparin crisis. Nat Biotechnol 2008;26(6): 621-3. [PubMed: 18536680]
3. U.S. Department of Health & Human Services. U.S. Food and Drug Administration. Information on Adverse Event Reports and Heparin. Online. 2009 Nov. Available from URL: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM112669>
4. Tieleman C, Madhoun P, Lenaers M, Schandene L, Goldman M, Vanherweghem JL. Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors. Kidney Int 1990;38(5):982-4. [PubMed: 2266684]
5. Verresen L, Waer M, Vanrenterghem Y, Michielsen P. Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis. Lancet 1990;336(8727):1360-2. [PubMed: 1978172]
6. Guerrini M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A, et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008;26(6):669-75. [PubMed: 18437154]

7. Maruyama T, Toida T, Imanari T, Yu G, Linhardt RJ. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. *Carbohydr Res* 1998;306(1-2):35–43. [PubMed: 9691438]
8. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. *N Engl J Med* 2008;358(23):2457–67. [PubMed: 18434646]
9. Ramacciotti E, Wahi R, Messmore HL. Contaminated heparin preparations, severe adverse events and the contact system. *Clin Appl Thromb Hemost* 2008;14(4):489–91. [PubMed: 18815138]
10. Silverberg M, Diehl SV. The activation of the contact system of human plasma by polysaccharide sulfates. *Ann N Y Acad Sci* 1987;516:268–79. [PubMed: 2449841]
11. van der Graaf F, Keus FJ, Vlooswijk RA, Bouma BN. The contact activation mechanism in human plasma: activation induced by dextran sulfate. *Blood* 1982;59(6):1225–33. [PubMed: 6177360]
12. Cyr M, Lepage Y, Blais C Jr, Gervais N, Cugno M, Rouleau JL, et al. Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma. *Am J Physiol Heart Circ Physiol* 2001;281(1):H275–83. [PubMed: 11406494]
13. Desormeaux A, Moreau ME, Lepage Y, Chanard J, Adam A. The effect of electronegativity and angiotensin-converting enzyme inhibition on the kinin-forming capacity of polyacrylonitrile dialysis membranes. *Biomaterials* 2008;29(9):1139–46. [PubMed: 18078988]
14. Krieter DH, Grude M, Lemke HD, Fink E, Bonner G, Scholkens BA, et al. Anaphylactoid reactions during hemodialysis in sheep are ACE inhibitor dose-dependent and mediated by bradykinin. *Kidney Int* 1998;53(4):1026–35. [PubMed: 9551414]
15. Keire DA, Trehy ML, Reepmeyer JC, Kolinski RE, Ye W, Dunn J, et al. Analysis of crude heparin by (1)H NMR, capillary electrophoresis, and strong-anion-exchange-HPLC for contamination by over sulfated chondroitin sulfate. *J Pharm Biomed Anal* 51(4):921–6. [PubMed: 19959313]
16. Trehy ML, Reepmeyer JC, Kolinski RE, Westenberger BJ, Buhse LF. Analysis of heparin sodium by SAX/HPLC for contaminants and impurities. *J Pharm Biomed Anal* 2009;49(3):670–3. [PubMed: 19167854]
17. Decarie A, Drapeau G, Closset J, Couture R, Adam A. Development of digoxigenin-labeled peptide: application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues. *Peptides* 1994;15(3):511–8. [PubMed: 7937327]
18. Raymond P, Drapeau G, Raut R, Audet R, Marceau F, Ong H, et al. Quantification of des-Arg9-bradykinin using a chemiluminescence enzyme immunoassay: application to its kinetic profile during plasma activation. *J Immunol Methods* 1995;180(2):247–57. [PubMed: 7714339]
19. Blais C Jr, Marc-Aurele J, Simmons WH, Louie G, Thibault P, Skidgel RA, et al. Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. *Peptides* 1999;20(4):421–30. [PubMed: 10458510]
20. Moreau ME, Thibault L, Desormeaux A, Chagnon M, Lemieux R, Robillard P, et al. Generation of kinins during preparation and storage of whole blood-derived platelet concentrates. *Transfusion* 2007;47(3):410–20. [PubMed: 17319820]
21. Bawolak MT, Gera L, Morissette G, Stewart JM, Marceau F. B-9972 (D-Arg-[Hyp3,Igl5,Oic7,Igl8]-bradykinin) is an inactivation-resistant agonist of the bradykinin B2 receptor derived from the peptide antagonist B-9430 (D-Arg-[Hyp3,Igl5,D-Igl7,Oic8]-bradykinin): pharmacologic profile and effective induction of receptor degradation. *J Pharmacol Exp Ther* 2007;323(2):534–46. [PubMed: 17699739]
22. Pruneau D, Paquet JL, Luccarini JM, Defrene E, Fouchet C, Franck RM, et al. Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist. *Immunopharmacology* 1999;43(2-3):187–94. [PubMed: 10596852]
23. Bachvarov DR, Houle S, Bachvarova M, Bouthillier J, Adam A, Marceau F. Bradykinin B(2) receptor endocytosis, recycling, and down-regulation assessed using green fluorescent protein conjugates. *J Pharmacol Exp Ther* 2001;297(1):19–26. [PubMed: 11259523]
24. Rice, J. Mathematical statistics and data analysis. Belmont: Duxbury Press; 1995.
25. Nuijens JH, Huijbregts CC, Eerenberg-Belmer AJ, Abbink JJ, Strack van Schijndel RJ, Felt-Bersma RJ, et al. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis. *Blood* 1988;72(6):1841–8. [PubMed: 3264190]

26. Willemin WA, te Velhuis H, Lubbers YT, de Ruig CP, Eldering E, Hack CE. Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. *J Immunol* 1997;159(4):1953–60. [PubMed: 9257861]
27. Adam A, Albert A, Boulanger J, Genot D, Demoulin A, Damas J. Influence of oral contraceptives and pregnancy on constituents of the kallikrein-kininogen system in plasma. *Clin Chem* 1985;31(9):1533–6. [PubMed: 3849362]
28. Adam A, Azzouzi M, Boulanger J, Ers P, Albert A, Damas J, et al. Optimized determination of plasma prokallikrein on a Hitachi 705 analyser. *J Clin Chem Clin Biochem* 1985;23(4):203–7. [PubMed: 3847464]
29. Blossom DB, Kallen AJ, Patel PR, Elward A, Robinson L, Gao G, et al. Outbreak of adverse reactions associated with contaminated heparin. *N Engl J Med* 2008;359(25):2674–84. [PubMed: 19052120]
30. Decarie A, Adam A, Couture R. Effects of captopril and Icatibant on bradykinin (BK) and des [Arg9] BK in carrageenan-induced edema. *Peptides* 1996;17(6):1009–15. [PubMed: 8899821]
31. Molinaro G, Gervais N, Adam A. Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach. *Stroke* 2002;33(6):1712–6. [PubMed: 12053016]
32. Carranza YE, Anderson D, Doctor V. Effect of oversulfated chondroitin-6-sulfate or oversulfated fucoidan in the activation of glutamic plasminogen by tissue plasminogen activator: role of lysine and cyanogen bromide-fibrinogen. *Blood Coagul Fibrinolysis* 2008;19(1):60–5. [PubMed: 18180617]
33. Carranza YE, Durand-Rougey C, Doctor V. Effect of oversulfation on the chemical and biological properties of chondroitin-4-sulfate. *Blood Coagul Fibrinolysis* 2008;19(6):483–7. [PubMed: 18685430]
34. Renaux JL, Thomas M, Crost T, Loughraieb N, Vantard G. Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH. *Kidney Int* 1999;55(3):1097–103. [PubMed: 10027949]
35. Baglin T, Barrowcliffe TW, Cohen A, Greaves M. Guidelines on the use and monitoring of heparin. *Br J Haematol* 2006;133(1):19–34. [PubMed: 16512825]
36. Adam A, Desormeaux A, Moreau ME. Physiopathology of the acute adverse effects of angiotensin-converting-enzyme inhibitors. *Bull Acad Natl Med* 2007;191(7):1433–43. discussion 1443–4. [PubMed: 18447063]
37. Sabourin T, Guay K, Houle S, Bouthillier J, Bachvarov DR, Adam A, et al. Absence of ligand-induced regulation of kinin receptor expression in the rabbit. *Br J Pharmacol* 2001;133(7):1154–62. [PubMed: 11487527]
38. Liu H, Zhang Z, Linhardt RJ. Lessons learned from the contamination of heparin. *Nat Prod Rep* 2009;26(3):313–21. [PubMed: 19240943]

Figure 1.

Panel A- Mean kinetic profiles (n=6) of BK obtained when plasma (90%) was incubated with 100 μg/mL Dxs (●), 100 μg/mL OSCS (○) and PBS (□) in the presence of an ACEi. **Panel B** shows representative AUCs (n=3) corresponding to kinetic profiles of the control plasma, Dxs (■) and OSCS (□) at 1, 10, 100 and 1000 μg/mL. Error bars correspond to SEM; if values are small, bars are missing. *p<0.0001 compared to control plasma.

A

B

Figure 2.

Panel **A**- Mean kinetic profiles (n=3) of BK measured when plasma was activated with 100 $\mu\text{g/mL}$ OSCS (■), 100 $\mu\text{g/mL}$ CSA (□), 100 $\mu\text{g/mL}$ CSB (○) or 100 $\mu\text{g/mL}$ of non-contaminated heparin (●) in the presence of an ACEi. Panel **B** represents AUCs (n=3) corresponding to the kinetic profiles of panel A. Error bars correspond to SEM; if values are small, bars are missing. * $p < 0.002$ compared to control plasma, $^{\infty}p < 0.0001$ compared to OSCS.

Figure 3.

Representative AUCs (n=3) corresponding to total BK released during 120 minutes when 100 µg/mL of Dxs (■) or OCS (□) activates different dilutions of plasma (90,80,60,50,40 and 20%) in presence of an ACEi. Error bars correspond to SEM.

Figure 4. Mean kinetic profile (n=3) of BK obtained when diluted plasma (50%) was activated by 100 $\mu\text{g/mL}$ OSCS in the absence (●) or in presence (○) of an ACEi. The upper right panel illustrates AUCs corresponding to both kinetic profiles. Error bars correspond to SEM. * $p < 0.0001$.

Figure 5.

Mean kinetic profile (n=6) of BK obtained when diluted plasma was incubated with PBS (□), 410 µg/mL of non-contaminated (●) or 100 µg OCS contaminated (○) heparin in presence of an ACEi. The lower left and right panels represent respectively the AUCs and the maximum concentration corresponding to both kinetic profiles. Error bars correspond to SEM.

*p<0.0001.

Figure 6.

Plots that demonstrate the effect of heparin contamination (percentage of OSCS) on the peak concentration (A) and total (B) BK released during 120 min incubation of diluted plasma (50%) with 410 $\mu\text{g/mL}$ of non-contaminated heparin spiked with OSCS(■) contaminated heparin(●) or contaminated heparin causing AR (○) with an ACEi (n=6). Error bars correspond to SEM; if values are small, bars are missing. * $p < 0.01$ compared to non contaminated heparin.

Figure 7.

Signaling responses induced by human plasma extracts in lysates of HEK 293 cells stably expressing B₂R-GFP. **A.** Immunoblots for phospho-ERK1/2 and total ERK1/2 in response to diluted reconstituted plasma extracts (1:45) previously incubated with OSCS, contaminated heparin (CHep), DxS or with no reagent (plasma) corresponding respectively to a separately measured and calculated immunoreactive BK concentration of 5.6, 4.8, 18.1 and 0.0 pmol/mL for the 1:45 dilution of the reconstituted extract. Cells were stimulated for 10 minutes before lysis. Controls (Ctrl) are extracts of unstimulated Hek 293 cells. **B.** Effect of authentic BK or of various dilutions of extracts from contaminated heparin- or OSCS-treated plasmas (10 min stimulations). **C.** Antagonist effect of LF 16-0687 (1 μ M; applied 10 min before extracts) on the activation of ERK1/2 induced by human plasma extracts.

Table 1

OSCS concentration in the different samples of heparin.

Sample #	OSCS concentration (w/w)
Heparin spiked with OSCS	
1	0
2	9.7
3	4.7
4	1.1
Heparin contaminated with OSCS	
5	1.3
6*	3.1
7	5.9
8	10
9*	16.7
10*	24.3

* AR have been reported in association with these samples.